Lysosomal storage disorders (LSDs) are rare inherited debilitating and often fatal disorders. Caused by mutations of lysosomal proteins, they are characterized by the accumulation of undegraded material in lysosomes and by lysosomal dysfunction. While the LSDs are multisystemic diseases, the majority present neurologic symptoms and neurodegeneration. Only very recently has a role emerged for mitochondrial dysfunction in the pathophysiology of some LSDs, suggesting a direct or indirect impact of lysosomal dysfunction on mitochondria. Moreover, mitochondrial damage may also cause lysosomal dysfunction, further supporting the activity of common signaling pathways and cross-talk between the two organelles. Thus, the interface between lysosomal and mitochondrial (dys)function is emerging as an important contributor to the pathogenesis of the LSDs and other neurodegenerative disorders. In this review, we explore the mechanisms linking lysosomal and mitochondrial dysfunction, in order to assess whether specific mitochondrial pathways represent a new therapeutic frontier in the management of the LSDs.
Interestingly, two recent studies also showed that primary mitochondrial dysfunction could induce lysosomal dysfunction [23, 24] . Indeed, T cells from mice deficient in mitochondrial transcription factor A (TFAM), were found to present mitochondrial defects and decreased respiration; this was associated with increased nuclear translocation of TFEB, weaker lysosomal calcium mobilization, reduced lysosomal enzyme activity and sphingomyelin accumulation, which are all relevant parameters for the evaluation of lysosomal function [23] . Similarly, abnormal lysosomes were observed in neurons and brains from mice lacking the mitochondrial protein apoptosis inducing factor (AIF) [24] . Moreover, in mouse embryonic fibroblasts (MEFs) from Optic Atrophy Protein 1 (OPA1) knockout mice for (a protein involved in the regulation of mitochondrial cristae morphology), accumulation of lysosomes, dysregulation of lysosomal pH, as well as decreased in the activity of the lysosomal enzyme cathepsin B were observed [24] . The lysosomal defects were at least partially rescued using antioxidant naturally present in cells like N-acetylcysteine or Coenzyme Q 10 to treat cells in culture, suggesting that increased free radical generation from damaged mitochondria might mediate altered lysosomal biology [24] . Collectively, these studies have suggested a link between mitochondrial and lysosomal function, but whether this represents a reciprocal crosstalk remains to be determined.
Interestingly, one of the signaling pathways involved in the activation of autophagy -the mechanism that allow cells to degrade and recycle dysfunctional and unneeded cellular components --(see Box 4), AMP-activated protein kinase (AMPK) pathway, is regulated by the AMP/ATP ratio and by calcium levels [25] . In particular, ATP depletion or increased cytosolic calcium concentration can both activate AMPKα. This in turn inhibits mechanisticTarget Of Rapamycin (mTOR), activating the lysosomal and autophagy master regulator TFEB, and inducing autophagy in human immortalized cell lines and in mouse models [26] [27] [28] . These findings lend further support to the tightly integrated connection between mitochondrial and lysosomal function. The functional interplay between these organelles might also be facilitated by a spatial dialogue, coordinating the localization and trafficking of these structures. In fact, it was recently shown that the changse in the expression level of the protein RAB26 are responsible for the relocalization of lysosomes in a secretory pancreatic cell lines that in turn leads to changes in mitochondria localization [29] .
Studies of lysosomal and mitochondrial biology support the hypothesis that lysosomal dysfunction negatively affects mitochondrial function, and vice versa. However, even if a strong reciprocal interconnection between lysosomal and mitochondrial function exists, dissecting the specific mechanisms by which these affect each other remains challenging.
Mitochondrial Impairment in LSDs
All the LSDs described in Box 1 present some form of mitochondrial dysfunction associated with a primary lysosomal impairment, (summarized in Table 1 ), affecting the CNS and other tissues, suggesting that impaired mitochondrial function may be a common pathogenic feature of these disorders. However, the degree and nature of the mitochondrial damage reported vary considerably depending on experimental models used.
Morphological changes have been the easiest to detect, mainly through transmission electron microscopy (TEM) and fluorescence imaging microscopy (see examples in ref. [11] and [30] ), which mostly reveal an abnormal mitochondrial network, i.e. mitochondrial fragmentation or elongation.
These abnormalities are in most cases associated with mitochondrial bioenergetic dysfunction, quantified as a reduced mitochondrial membrane potential and/or impaired mitochondrial respiration.
In neurons and astrocytes from a mouse model for neuropathic GD [11] and in fibroblasts from GD patients [31] , mitochondria have been shown to be small and fragmented, exhibiting reduced membrane potential , mitochondrial complex levels and activity, as well as impaired respiration.
Experimental models of Niemann Pick disease C (NPC) also present alterations in mitochondrial morphology and function (Box 1). In yeast cells lacking Ncr1p, an orthologue of the mammalian protein Niemann Pick C1 (NPC1, an intracellular cholesterol transporter whose mutations cause NPC), mitochondria are fragmented, and both mitochondrial membrane potential and oxygen consumption rate are reduced [32] . Two independent studies of fibroblasts from patients carrying mutations in NPC1 gave conflicting results: one described disruption of the mitochondrial network, but increased mitochondrial mass corresponding to increased oxygen consumption [33] . The other study reported reduced mitochondrial membrane potential but no effect on mitochondrial mass or morphology [34] . Neurons derived from NPC1 knockdown human Embryonic Stem Cells (hESCs) showed accumulated fragmented mitochondria and mitochondrial proteins, without any measurable change in mitochondrial membrane potential [35] . These latest findings were in agreement with those from NPC1 knockout (KO) mice, in which neurons presented smaller rounded mitochondria with reduced membrane potential, decreased ATP synthase activity and reduced ATP generation [36] .
A mouse model of Multiple Sulfatase Deficiency (MSD) generated by knocking out Sumf1, which encodes for the protein Sulfatase-modifying factor 1, involved in the pathway of sulfatase oxidation, was again associated with mitochondrial fragmentation, accumulation of dysfunctional mitochondria and impaired ATP production in brain and liver [37, 38] Systematic studies of mitochondrial fission and fusion in LSDs, are few and far between, despite the widely described profound changes in mitochondrial morphology. Indeed, the functional significance of altered mitochondrial morphology is not yet clear. When mitochondrial fragmentation in primary neurons from a GD mouse model was rescued by overexpressing the dominant-negative fission mediator GFP-Drp1K38A. This is a mutant of the GTPase DynaminRelated Protein 1 (Drp1) which is defective in GTP binding, causing reduced mitochondrial fission and therefore mitochondrial elongation. Mitochondrial function was unaffected by this change in morphology, [11] showing that mitochondrial fragmentation was a consequence and not a cause of mitochondrial dysfunction. It would be interesting to determine whether the same phenomenon applies to other LSDs.
Another important aspect of mitochondrial biology is mitochondrial trafficking, especially in the CNS. Mitochondrial transport to regions of the cell where ATP demand is high needs to be finely tuned, especially in large cells with long processes such as neurons, where energy consumption may be highest at remote outposts [54, 55] . The Ca 2+ buffering capacity of mitochondria in specific cellular regions also has important implications for neuronal function by controlling the spatiotemporal patterning of intracellular Ca 2+ signaling [54] . Mitochondrial transport mechanisms are understudied in the LSDs, but a recent study reported a significant reduction in the number of moving mitochondria and in their speed in vitro in axons treated with psychosine, a lipid that accumulates in Krabbe disease [56] .
Causes and Consequences of Mitochondrial Dysfunction in LSDs
The specific molecular mechanisms that lead to neurodegeneration in LSDs remain poorly understood. Here, we consider candidate causes and consequences of mitochondrial damage associated with primary lysosomal dysfunction (see Figure 1 , Key Figure) . A schematic representation of the interplay between lysosomal dysfunction and mitochondrial dysfunction is shown in Figure 1 , where the contribution of autophagy impairment, ROS production and calcium homeostasis dysregulation is also presented.
Ultimately, it seems critical to establish i) whether there is a common molecular mechanism that culminates in mitochondrial dysfunction in LSDs; ii) the extent to which mitochondrial dysfunction contributes to the disease phenotype and iii) whether the pathways leading to mitochondrial dysfunction represent viable potential therapeutic targets.
Impaired Autophagy and Mitophagy
Dysregulation of autophagic lysosomal pathways has been described in most of the lysosomal storage disorders we consider here [11,31,35,37- , while autophagy can also be triggered by increased free radical generation [67] . No information on these alternate mitophagy pathways in LSDs are available at the moment and more studies will be needed to clarify their relevance in the etiopathogenesis and progression of these diseases.
The PINK1/Parkin pathway has been most intensively studied in relation to PD, as mutations of PINK1 or PARK2, which encodes for parkin, are genetic causes of early onset PD. Specific impairment of mitophagy through impaired Parkin/Pink1 recruitment or function has also been investigated in relation to GD and MSD in mouse models. In primary neurons cultured from a GD mouse model, colocalization of autophagosomes and mitochondria was reduced, suggesting reduced recycling of damaged mitochondria [11] . However, mitochondria in GD neurons retained the capacity to recruit
Parkin following treatment by a mitochondrial uncoupler --carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, FCCP --, which transports hydrogen ions through mitochondrial membranes leading to collapse of the mitochondrial membrane potential (ucoupling respiration from oxidative phosphorylation), suggesting that the Parkin-mediated mitophagy pathway was functional. On the other hand, in GD neurons, under basal conditions, depolarized mitochondria did not recruit Parkin, suggesting that mitochondrial membrane potential was not sufficiently compromised to trigger mitophagy through PINK1 accumulation. Conversely, a study of GD human fibroblasts showed increased co-localization between mitochondria and autophagosomes [31] , suggesting that differences may arise from the use of different experimental models, not only because mouse neurons and human fibroblasts were used, respectively, but also because in the first case the cells completely lack the enzyme, while in the second case fibroblasts carry single point mutations that cause a loss of enzyme folding, expression and activity, but not its complete depletion. In MSD mouse liver (but not brain), the expression level of Parkin was reduced, relative to control tissue. However, its recruitment to mitochondria upon depolarization to trigger mitophagy was effective, pointing toward a tissue-specific defect in Parkin turnover which was not seen in the brain, rather than toward an impairment of this specific mitophagy pathway [38] .
When mitophagy is disrupted, either because of a negative feedback mechanism that inhibits the autophagic pathway upon lysosomal impairment, or through dysfunctional regulation of autophagy and autophagolysosome formation, it seems plausible that impaired/defective mitochondria could accumulate within a cell. Dysfunctional mitochondria may not have the capacity to support normal bioenergetic demands, and consequently, cell function might suffer. Furthermore, a damaged respiratory chain will tend to generate reactive oxygen species (ROS) at an increased rate, which results in oxidative damage to proteins, lipids and DNA, a common feature of several LSDs [30, 32, [68] [69] [70] [71] .
Macromolecules and protein aggregates can also accumulate when autophagy is impaired and this may be of further detriment to mitochondrial function, as discussed below.
Oxidative Stress
ROS are highly reactive oxygen radical species that can cause oxidative damage to proteins, lipids and DNA. As an engine driven by redox and electron transfer reactions, the mitochondrial respiratory chain is one of the major mechanisms generating ROS within most cell types, often viewed as an inevitable by-product of oxidative phosphorylation. ROS are scavenged by antioxidant defences which limit net ROS generation. In healthy cells, low levels of ROS generation may be required for various signaling pathways [72] , and therefore, the balance between ROS production and ROS scavenging must be finely tuned. An increase in net ROS generation exceeding the antioxidant scavenging capacity is defined as oxidative stress, leading to lipid peroxidation, oxidation of proteins and DNA damage. In human GD fibroblasts and gba1-/-mice neurons, Increased ROS production or mitochondrial dysfunction could be rescued when cells in culture were treated with mitochondria-targeted antioxidants like Coenzyme Q or MitoQ, respectively [11, 31] , consistent with a mitochondrial origin for the generation of ROS. This suggests that enhanced oxidative stress or increased vulnerability to it may be a feature of LSDs, and that scavenging mitochondrial ROS may be a possible therapeutic approach to consider.
More in general, these various findings suggest that the balance between ROS generation and antioxidant defence, such as superoxide dismutases, catalase and glutathione, may be disrupted in several LSDs and that in some models, antioxidant defences may be defective or inadequate to scavenge increased ROS generation. In NPC human fibroblasts, exhibiting decreased ROS production, decreased superoxide dysmutase 1 and 2 (SOD1 and SOD2, responsible for the dismutation of superoxide in cell cytoplasm or in mitochondria, respectively) protein expression was observed [33] . In contrast, in all other models showing increased ROS production, the levels of antioxidant defences varied considerably. For instance, In MPS IV patient erythrocytes, the antioxidant glutathione, a tripeptide that reduces disulfide bonds formed within cytoplasmic proteins and is therefore oxidized to glutathione disulfide, was decreased, while SOD activity was increased [68] . In NCL human fibroblasts, the activity of the enzyme catalase, responsible for catalyzing the formation of water and oxygen from H 2 O 2 , was decreased [58] , and in a NPC yeast model and in NPC human fibroblasts, SOD2 and/or catalase activity and glutathione levels were decreased [32, 69] , while SOD2 mRNA and protein levels were reduced in GM2 gangliosidosis mouse brains [30] . Furthermore, extensive studies of oxidative pathways in the cerebellum of NPC mouse models [74] as well as from post mortem material from NPC patients [75] , further suggest increased oxidative stress in NPC.
From the available evidence in the literature, it seems clear that oxidative stress is a common feature of different LSDs which is also a feature of other neurodegenerative disorders, and a possible therapeutic target. However, at this stage the contribution of mitochondrial ROS or of other ROS sources is still unclear, as well as the degree of dysregulation of the different antioxidant defences within mitochondria and in the cell cytoplasm. All these pathways deserve further systematic investigations in LSDs.
Mitochondrial Calcium Dysregulation
Considering the severe mitochondrial damage observed in many LSDs, it is not surprising that Moreover, neurons showed increased vulnerability to excitotoxicity. In another study, increased Ca 2+ responses to glutamate or caffeine--likely due to increased Ca 2+ release from the ER--were observed in a pharmacological rat neuronal model of GD, leading to glutamate-induced excitotoxicity [84] . The machinery that allows Ca 2+ to be taken up by mitochondria, i.e. the MCU complex, has not been studied at all in the LSDs. Interestingly, MCU expression controls excitotoxicity [85] , further highlighting a need for studies focused on the MCU complex in these diseases.
With regard to apoptotic processes, the application of psychosine to neurons in vitro was found to raise cytosolic calcium concentration, which was associated with transient mitochondrial membrane hyperpolarization followed by depolarization; this eventually led to apoptosis [73] . The accumulation of GM1 in mouse embryonic fibroblasts (MEFs) from beta-gal -/-mice (a model of GM1 The presence of storage material in lysosomes, the alterations in membranes composition due to changes in the overall lipid contents and mitochondrial damage may all be contributing to alteration in the Ca 2+ handling, but further causes are probably still unknown. Once elucidated, these mechanisms may also be target for designing new therapies.
Accumulation of molecules and macromolecules in LSDs
The most obvious impact of lysosomal impairment in LSDs is the accumulation of macromolecules in the endo-lysosomal compartment and cytoplasm. for example, they are found in ageing brains but their accumulation is also a major histopathological feature of a number of LSDs [94] .
Lipofuscin granules are not inert: they can be chemically reactive at the cell surface, binding metals, and driving further protein and lipid oxidation that can affect lysosomal and proteasome function [93] . Moreover, remarkably, one of the main constituents of lipofuscin granules is the ATP-synthase subunit c, especially in NCL across different species [43, 44, 57, 95] . This suggests a role for mitochondrial damage in the formation of lipofuscins although the mechanism by which the protein is singled out to accumulate in these structures remains obscure.
Accumulation of alpha-synuclein (aS) and aS aggregates is another interesting and potentially important feature of several LSDs. aS is a protein strongly implicated in sporadic and genetic forms of PD that normally localizes primarily at presynaptic terminals in the mammalian brain [96] . In pathological conditions, aS tends to aggregate and form oligomers and amyloid fibrils that eventually deposit in Lewy Bodies which are protein and lipid aggregates found in PD and in other synucleinopathies [97] . How different aS species contribute to the disease etiopathogenesis is still under debate, but interestingly aS accumulation and aggregation has been associated with mitochondrial dysfunction and fragmentation in several cellular models of PD [98] [99] [100] . However, it is currently unclear whether aS accumulation is a primary cause of mitochondrial damage in those models or has a secondary effect of generating ROS production and/or impaired autophagy. Possible mechanisms previously reported include direct damage by aS oligomers at the mitochondrial membrane in cells and neurons overexpressing the protein [99, 101] or secondary effects due to altered calcium signaling in the presence of aS oligomers [102] or to autophagy inhibition caused by aS accumulation in the cytoplasm [103, 104] . Although speculative, it is possible that a mechanism such as this might also occur in certain LSDs, feeding into a vicious cycle to cause further accumulation of dysfunctional mitochondria when quality control pathways become impaired.
Indeed, aS aggregates have been documented in a number of LSDs --in post mortem material from brain samples of patients with GD [105] , and GM2 gangliosidosis [106] . Lewy Bodies were also noted in the brains of patients with NPC [107] while neurons in the brains of MPS III subjects were reactive for phosphorylated aS [108] . aS oligomers were also found in the plasma of patients with different
LSDs, including GD, NPC and Krabbe disease [109] and in NPC lymphoblasts [110] . Many LSD rodent models (for GD, NCL, GM2 gangliosidosis, MPS III and MSD) that recapitulate the features of these diseases to a certain degree, also show aS accumulation, aggregation or overexpression [11, 30, 37, 45] .
For PD and for all other neurodegenerative disorders presenting aS accumulation, it is difficult to define whether aS accumulation is a cause or an effect of mitochondrial dysfunction, or both.
However, in a Hexb -/-mouse model for GM2 gangliosidosis, silencing aS by generating double knock out mice Hexb -/-SNCA -/-was found to ameliorate mitochondrial function, suggesting that aS might contribute to mitochondrial pathology, at least in this model [30] . In an MPS III mouse model, GM2 and GM3 gangliosides were increased in total brain extracts and their colocalization to mitochondria was verified by immunocytochemistry in brain slices using specific antibodies against GM2-GM3 and against the mitochondrial marker cytochrome c oxidase (complex IV) [40] . In these models, mitochondrial dysfunction was also observed, suggesting a mechanistic link between lipid accumulation in mitochondria and impaired bioenergetic function.
More work is required to understand how the accumulation occurs, how it is responsible for mitochondrial damage and how it can be prevented. Moreover, further research is warranted to determine whether the accumulation of lipids observed in other LSDs especially occurs in mitochondria.
Concluding Remarks
The fact that most of the neurological symptoms in the LSDs cannot be treated with available Pompe disease is caused by mutations in the gene encoding the lysosomal enzyme acid α-glucosidase (GAA), which converts glycogen to glucose, and leads to glycogen accumulation. The main symptoms are cardiomyopathy and muscle weakness, which can vary depending on severity, and in most cases lead to respiratory failure and death. It was also shown a relevant damage to central nervous system and in particular to motor neurons.
Box 2 -Therapeutic Approaches: Present and Future
The main available treatments for LSDs rely on replacing the dysfunctional enzyme (enzyme replacement therapy, ERT) or restoring enzyme activity [5] . However, these approaches do not help with the neurological symptoms because most of these molecules cannot cross the blood brain barrier. Recent advances in ERT for the treatment of neuropathic LSDs were achieved by fusing the enzyme to peptides or proteins that increase brain delivery. Other options are intracerebroventricular injection or nanoparticle-mediated delivery of the enzymes. In vivo (systemic or CNS-directed) or ex vivo gene therapy are also under evaluation [111] .
Given the profound mitochondrial dysfunction described in some LSDs, treatments that affect mitochondrial function may prove helpful especially in neurons. In particular, it seems clear that interventions that reduce oxidative stress through delivery of antioxidants such as MitoQ may be beneficial [11, 31] . Other approaches might potentially target mitochondria, impacting mitochondrial morphology, improving mitochondrial respiration to restore ATP levels or modulating calcium levels or handling.
Accumulation of damaged mitochondria can also be harmful. Thus, strategies that enhance autophagy might prove valuable, bearing in mind that lysosomal overload is not desirable. This could be achieved by inhibiting mTOR, which successfully restored ATP levels in iPSC-derived neurons generated from a patient with an ATP synthase deficiency [112] , or by acting on other upstream pathways. Another strategy may involve direct manipulation of TFEB activity to promote autophagy and lysosomal biogenesis. Interestingly, TFEB was found to be predominantly localized in the nucleus in MEFs from MPS-II, MPS-III and MSD, suggesting that the TFEB signaling pathway is activated in these diseases, probably in response to lysosomal stress [113] . It remains to be determined whether further activation may be effective in removing dysfunctional mitochondria.
Another approach that may be beneficial concerns the targeted removal of aS aggregates, which are toxic and can damage mitochondria [99] ; this might be potentially achieved either by enhancing autophagy [114, 115] or via immunotherapy, an approach that has been effective in some PD models [116, 117] . Nonetheless, further preclinical studies are warranted to validate these possibilities.
Box 3 Lysosome Biology
Lysosomes are organelles enclosed by a single membrane in which more than 50 hydrolytic enzymes break down macromolecules and organelles that cells target for degradation. Lysosomal degradation is essential to avoid the accumulation of damaged or misfolded proteins or lipids, damaged organelles as well as pathogens.
The optimal pH for most lysosomal enzymes is acidic [7] . An acidic pH between 4.5 and 5 [87] , is achieved within lysosomes by the proton-pumping V-type adenosine triphosphatase (ATPase) [118] , in concert with the chloride channel 7 (CIC-7), the nonselective cation channel mucolipin 1 (TRPML1), the two-pore calcium channels (TPC1 and TPC2) and the potassium channel TMEM175 [119] [120] [121] [122] [123] .
Hydrolytic enzymes are synthesized in the ER and Golgi and transferred to lysosomes through different mechanisms [124] . Substrates destined for degradationd within lysosomes are delivered to these organelles by endocytosis --in the case of extracellular material--and by autophagy --for disposal of intracellular waste [125] .
It was long thought that the role of lysosomes was limited to the degradation of substrates, however this view has now changed and it is clear that these organelles are involved in several other crucial processes which include regulation of signaling pathways, calcium signaling as well as energy and nutrient metabolism [125, 126] .
Lysosome biogenesis is regulated by the transcription factor EB (TFEB). TFEB activates the coordinated lysosomal expression and regulation (CLEAR) network, which enhances the expression of lysosomal genes, increasing the number of lysosomes, but also increasing the expression of other proteins involved in lysosomal cellular clearance mechanisms such as autophagy [26, 113] . TFEB is activated by Ca 2+ release from lysosomes, further emphasising a central role of lysosomes in cell signaling [126] . Mitochondria are also involved in other processes including the regulation of apoptosis and calcium homeostasis. This is particularly important for neuronal function as calcium signaling plays a central role in neuronal signaling. Mitochondrial Ca 2+ uptake shapes calcium signals in the cytoplasm through a transmembrane protein, a Ca 2+ selective channel localized at the inner mitochondrial membrane, termed the Mitochondrial Calcium Uniporter (MCU) [127] . The MCU mediates calcium uptake into mitochondria, which regulates not only cell signaling but also aerobic metabolism and cell death [128] . MCU activity is tightly regulated by different interactors that form the MCU complex, including the Essential MCU Regulator (EMRE) and MICU1/MICU2 proteins [129] . The activity of the complex is regulated directly by the concentration of cytosolic calcium to which it is exposed. Calcium uptake is also dependent on the mitochondrial membrane potential, i.e. calcium accumulation is reduced in depolarized mitochondria.
Given the importance of mitochondrial function in all cell types, a variety of mitochondrial quality control mechanisms have evolved that serve to remove damaged mitochondrial proteins or even entire organelles through the ubiquitin proteasome system and via autophagic degradation [130, 131] .
Box 4. Autophagic Mechanisms
Autophagy is a mechanism that allows the controlled and orderly removal of cellular waste, including damaged organelles and aggregated proteins, and recycling of useful cellular components.
Autophagy can be distinguished as macroautophagy, microautophagy and chaperone-mediated autophagy. During macroautophagy (referred to as 'autophagy' in this review), cytoplasmic material is sequestered into vesicles enclosed by a double membrane, termed autophagosomes, which then fuse with lysosomes. After formation of the autophagolysosomes, lysosomal enzymes degrade and recycle autophagosome cargo.
Mitophagy constitutes a type of autophagy specific to the removal of dysfunctional mitochondria by defined pathways (mitochondrial autophagy). It is widely regarded as especially important in maintaining cell health, since for example, a damaged mitochondrial electron transport chain is more likely to generate excessive free radical species leading to oxidative damage in a host cell.
Microautophagy is a special type of autophagy in which cytoplasmic material is engulfed into lysosomes/vacuoles by membrane invagination and then degraded.
Chaperone-mediated autophagy is a process of degradation of soluble cytosolic protein through their targeting to lysosomes by a chaperone-mediated selection.
Box 5. The Clinician's Corner
• LSDs account for most neurodegenerative disorders in children but no effective treatment for the neurological symptoms associated are available. The major therapeutic strategies for systemic symptoms are based on restoring or replacing the activity of a given dysfunctional enzyme, by using molecular chaperones, by providing the enzyme or by gene therapy.
Inhibition of substrate synthesis is also possible.
• Interesting similarities with other neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease are emerging: in particular, similar mechanisms cause mitochondrial dysfunction. Moreover, calcium dyshomeostasis and substrate/macromolecule accumulation may also be common pathways associated with the etiopathogenesis of LSDs and other prevalent neurodegenerative disorders.
• LSDs are rare diseases each of which presents a different phenotype for reasons that are still unclear. Therefore, the identification of common underlying targets as mitochondrial pathways may signpost a path to new putative therapeutic approaches. In healthy conditions, mitochondria are responsible for producting ATP through mitochondrial respiration , and oxidative phosphorylation, a process that leads to ROS production. ROS levels are controlled by antioxidant defences and are crucial to mantaining cell health. Mitochondria also manage calcium homeostasis by buffering calcium when needed.
In LSDs, dysfunctional lysosomes are associated with impaired autophagy, and therefore impaired mitophagy. This can lead to accumulation of dysfunctional mitochondria which can be further damaged by accumulated aggregates or macromolecules such as alpha synuclein. Dysfunctional mitochondria produce ATP less efficiently and an impaired respiratory chain may generate more ROS, while damaged mitochondria have a reduced capacity to buffer calcium. Impaired calcium handling may also be associated also with altered ER and lysosomal calcium signaling.
Aside from impaired mitophagy, other molecular mechanisms leading to mitochondrial dysfunction in LSDs, might potentially be linked to the relationship between mitochondria and lysosomes. Table 1 . LSDs and Mitochondrial Dysfunction at a Glance.
The table summarises published studies on mitochondria biology in LSDs, grouped according to the experimental approach used to examine changes in mitochondrial function and the models in which these features were studied. Findings vary depending on the models and on the methods used, suggesting that standardization would be helpful in clarifying the role of mitochondrial dysfunction in LSDs and the molecular mechanisms involved.
• Most LSDs show profound mitochondrial dysfunction. This is particularly relevant in neurons which have a strong dependence on oxidative phosphorylation for ATP production and on fine-tuning intracellular calcium levels governing neuronal signaling.
• Mitochondrial defects impact lysosomal function, suggesting a functional relationshippotentially reciprocal --between these two organelles.
• Lysosomal dysfunction in LSDs is associated with impaired autophagy, dysregulation of mitochondrial quality control pathways as well as accumulation of damaged mitochondria.
• Other new causes and/or consequences of mitochondrial dysfunction reported in LSDs include increased ROS production and oxidative stress, calcium dyshomeostasis.
• Damage mitochondria, calcium signaling and ROS unbalances may all be targets for the development of new therapeutic strategies.
• Alpha-synuclein aggregation, which is involved in neurodegeneration in Parkinson's disease, may be associated with mitochondrial dysfunction and neurons death in LSDs
Outstanding questions
• How does a primary lysosomal dysfunction impair mitochondrial function?
Most LSDs are caused by mutations in lysosomal proteins which lead to dysfunction of the autophagy /lysosomal pathway. Mitochondrial dysfunction has been identified, but the molecular mechanisms by which lysosome dysregulation lead to mitochondrial damage are still unclear and may vary according to the specific disease.
• how does a primary mitochondrial deficiency impair lysosomal function?
It was recently shown that deficiencies in TFAM or mitochondrial complexes can lead to lysosomal dysfunction resembling those present in LSDs, suggesting a link, perhaps reciprocal, between the two organelles.
• Are defects in lysosomal calcium signaling responsible for altered mitochondrial calcium handling?
• Are mitochondrial defects in LSDs primarily due to downstream deficiencies in mitochondrial quality control pathways or to a direct effect of lysosomal dysfunction affecting mitochondria?
• To what extent do lysosome storage materials in different LSDs contribute to mitochondrial dysfunction?
• Does the loss of products normally generated by lysosomal degradation, e.g. sphingolipids, affect mitochondrial function?
• What are the common or specific mechanisms that lead to mitochondrial dysfunction in different LSDs and other neurodegenerative disorders? LSDs present multiple forms of mitochondrial
